Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 1/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158572 | 0.69 | BBOX1 (0.58) | BBOX1EHMT2EHMT1TSHRALDH1A1 | |
| SCHEMBL7379226 | 0.69 | — | — | |
| Benzene Selenoic Acid SCHEMBL1440596 | 0.65 | — | — | |
| SCHEMBL3142465 | 0.65 | — | — | |
| Benzene Selenoic Acid SCHEMBL8752795 | 0.63 | BBOX1 (0.94) | BBOX1EHMT2EHMT1TSHRALDH1A1 | |
| Benzene Selenoic Acid SCHEMBL27636752 | 0.63 | BBOX1 (0.94) | BBOX1EHMT2EHMT1TSHRALDH1A1 | |
| SCHEMBL1165959 | 0.63 | BBOX1 (0.50) | BBOX1EHMT2EHMT1TSHRALDH1A1 | |
| Benzene Selenoic Acid SCHEMBL28844455 | 0.63 | BBOX1 (0.94) | BBOX1EHMT2EHMT1TSHRALDH1A1 | |
| Benzene Selenoic Acid SCHEMBL8752793 | 0.63 | BBOX1 (0.50) | BBOX1EHMT2EHMT1ALDH1A1TDP1 | |
| SCHEMBL1127796 | 0.61 | BBOX1 (0.56) | BBOX1EHMT2EHMT1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044224-A1 | Process for preparing 2-phenyl-3-aminobenzothiophenes | CONRAD PRESTON CHARLES (US) | 2004-03-04 | — | — | US | disclosed |
| EP-0979076-A4 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO b]THIOPHENES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-0979075-A4 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO b]THIOPHENES | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| WO-2002018364-A2 | PROCESS FOR PREPARING 2-PHENYL-3-AMINOBENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6087374-A | VIRICIDES INHIBITING THE GROWTH OF PICONAVIRUSES, SUCH AS RHINOVIRUSES, HEPATITUS VIRUSES, CARDIOVIRUSES, POLIOVIRUSES, ENTEROVIRUSES, COXSACKIEVIRUSES, ECHO VIRUS AND MENGO VIRUS | ELI LILLY AND COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| US-6075146-A | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6043360-A | Intermediates and a process for preparing benzo[B]thiophenes | ELI LILLY AND COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5914405-A | Process for preparing 3-substituted indazoles | ELI LILLY AND COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1999018080-A1 | PROCESS FOR PREPARING 3-SUBSTITUTED INDAZOLES | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908452-A2 | Process for preparing 3-substituted indazoles | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5852193-A | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0878474-A2 | Intermediates and a process for preparing benzo[b]thiophenes | ELI LILLY AND COMPANY (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998048793-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048787-A1 | INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048792-A1 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0875507-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998031363-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044224-A1 | Process for preparing 2-phenyl-3-aminobenzothiophenes | TPST2, SULT1A1, TYR | BBOX1 194/4885EHMT2 1720/4885EHMT1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.